血液病患者血清促红细胞生成素含量测定对贫血治疗临床意义

Study on the clinical effect of recombinant human erythropoietin levels in hematologic patients with anemia

目的：探讨基因重组人红细胞生成素（rhEPO）治疗血液病贫血的临床疗效及其影响因素,为rhEPO治疗血液病贫血的适应证选择提供理论基础。方法：对112例血液病贫血患者给予rhEPO治疗,6 000~10 000 IU,每日或隔日1次,皮下注射,10次为1个疗程,连续应用1~3个疗程,评价临床疗效和不良反应。结果：rhEPO治疗血液病贫血总有效率为61.6%（69/112）,其中血液肿瘤缓解组有效率为100.0%（38/38）、血液肿瘤未缓解组有效率为34.6%（18/52）、再生障碍性贫血组有效率为30.0%（3/10）、慢性病贫血组有效率为83.3%（10/12）。通过血清内源性促红细胞生成素水平（sEPO）与疗效关系分析,显示sEPO水平低者疗效[96.0%（48/50）]明显优于sEPO水平高者[33.9%（21/62）],未见明显不良反应。结论：rhEPO用于治疗sEPO水平偏低的血液肿瘤缓解后及慢性病贫血患者是有效的,而对于sEPO水平显著增高的贫血和其他血液肿瘤未缓解者疗效不理想。

Objective：To investigate the effect of recombinant human erythropoietin（rhEPO） in the treatment of hematologic patients with anemia.Methods：112 patients in hematologic with anemia were treated by rhEPO,6 000-10 000 IU,ih,qd or qod,for 10 days consisted of one course and every patient was received 1-3 courses of treatment.The clinical efficacy and adverse reactions of them were evaluated.Results：In all 112 patients in hematologic with anemia,the total efficiency rate was 61.6%（69/112）,efficiency rate in anemia with patients with remission tumor was 100.0%（38/38）,patients with no-remission tumor was 34.6%（18/52）,AA was 30.0%（3/10）,ACD was 83.3%（10/12）.The efficiency rate in patients of sEPO lower level was [96.0%（48/50）],and it was better than that of patients of sEPO higher level [33.9%（21/62）].There was no adverse reactions happened.Conclusion：The rhEPO is efficacious for anemia with patients in remission tumor and anermia of chronic disease,but with lowly efficacious in treating no-remission tumor.